First Tracks Biotherapeutics’ (TRAX) Buy Rating Reaffirmed at HC Wainwright

First Tracks Biotherapeutics (NASDAQ:TRAX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $30.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 51.36% from the stock’s previous close.

TRAX has been the topic of a number of other reports. UBS Group assumed coverage on First Tracks Biotherapeutics in a research report on Tuesday, April 21st. They set a “buy” rating and a $45.00 price objective on the stock. Leerink Partners began coverage on First Tracks Biotherapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $46.00 target price for the company. Wedbush assumed coverage on First Tracks Biotherapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $30.00 target price on the stock. Wall Street Zen upgraded First Tracks Biotherapeutics to a “hold” rating in a report on Saturday, May 2nd. Finally, Zacks Research upgraded First Tracks Biotherapeutics to a “hold” rating in a research report on Monday, April 27th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $38.25.

First Tracks Biotherapeutics Stock Performance

Shares of NASDAQ TRAX opened at $19.82 on Wednesday. First Tracks Biotherapeutics has a 12-month low of $14.72 and a 12-month high of $26.80. The firm’s 50-day simple moving average is $17.90.